{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T21:02:56Z","timestamp":1776373376949,"version":"3.51.2"},"reference-count":109,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":4955,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstert.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.fertnstert.2008.08.093","type":"journal-article","created":{"date-parts":[[2008,11,12]],"date-time":"2008-11-12T05:56:08Z","timestamp":1226469368000},"page":"S103-S113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"S","title":["Hormonal contraception: recent advances and controversies"],"prefix":"10.1016","volume":"90","member":"78","reference":[{"key":"10.1016\/j.fertnstert.2008.08.093_bib1","series-title":"Clinical gynecologic endocrinology and infertility","first-page":"867","article-title":"Oral contraception","author":"Speroff","year":"1999"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.contraception.2004.01.011","article-title":"Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera","volume":"70","author":"Jain","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.contraception.2006.03.008","article-title":"Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg","volume":"74","author":"Arias","year":"2006","journal-title":"Contraception"},{"issue":"Suppl 2","key":"10.1016\/j.fertnstert.2008.08.093_bib4","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0015-0282(01)03261-7","article-title":"Pharmacokinetic overview of Ortho Evra\/Evra","volume":"77","author":"Abrams","year":"2002","journal-title":"Fertil Steril"},{"issue":"Suppl 2","key":"10.1016\/j.fertnstert.2008.08.093_bib5","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0015-0282(01)03275-7","article-title":"Contraceptive efficacy and cycle control with the Ortho Evra\/Evra transdermal system: the analysis of pooled data","volume":"77","author":"Zieman","year":"2002","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib6","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1001\/jama.285.18.2347","article-title":"ORTHO EVRA\/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial","volume":"285","author":"Audet","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.contraception.2005.03.005","article-title":"Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive","volume":"72","author":"van den Heuvel","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/01.AOG.0000250968.82370.04","article-title":"Venous thromboembolism, myocardial infarction and stroke among transdermal contraceptive system users","volume":"109","author":"Cole","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib9","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0015-0282(01)01689-2","article-title":"Use of novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition","volume":"75","author":"Mulders","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/humrep\/16.3.469","article-title":"Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol","volume":"16","author":"Roumen","year":"2001","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1055\/s-2001-18643","article-title":"Progestin-releasing intrauterine systems","volume":"19","author":"Luukkainen","year":"2001","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0010-7824(94)90109-0","article-title":"Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial","volume":"49","author":"Andersson","year":"1994","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0010-7824(77)90001-4","article-title":"Comparative quantitation of menstrual blood loss with a d-norgestrel-releasing IUD and a Nova-T-copper device","volume":"15","author":"Nilsson","year":"1977","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0010-7824(01)00302-X","article-title":"Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years","volume":"65","author":"Hidalgo","year":"2002","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib15","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0002-9378(11)90607-3","article-title":"Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices","volume":"166","author":"Sivin","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib16","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1093\/humrep\/13.12.3371","article-title":"The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study","volume":"13","author":"Sivin","year":"1998","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0010-7824(98)00112-7","article-title":"Contraception with two levonorgestrel rod implants. A 5-year study in the United States and Dominican Republic","volume":"58","author":"Sivin","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib18","first-page":"71319","article-title":"Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel","author":"Funk","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib19","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1067\/mob.2001.117415","article-title":"Preclinical profiles of progestins used in formulations of oral contraceptives and hormone replacement therapy","volume":"185","author":"Hammond","year":"2001","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0010-7824(00)00133-5","article-title":"Drospirenone: pharmacology and pharmacokinetics of a unique progestogen","volume":"62","author":"Krattenmacher","year":"2000","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0015-0282(00)01747-7","article-title":"The emerging use of the 20-\u03bcg oral contraceptive","volume":"75","author":"Poindexter","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0010-7824(99)00109-2","article-title":"Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations","volume":"60","author":"Rosenberg","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003553.pub2","article-title":"Biphasic versus monophasic oral contraceptives for contraception","volume":"3","author":"Van Vliet","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib24","first-page":"771","article-title":"Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial","volume":"98","author":"Miller","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0010-7824(02)00445-6","article-title":"Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial","volume":"67","author":"Kwiecien","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib26","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(98)05718-3","article-title":"Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation","volume":"353","author":"Piaggio","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0010-7824(98)00042-0","article-title":"New estimates of the effectiveness of the Yuzpe regimen of emergency contraception","volume":"57","author":"Trussell","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0010-7824(99)00018-9","article-title":"Updated estimates of the effectiveness of the Yuzpe regimen of emergency contraception","volume":"59","author":"Trussell","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(98)05145-9","article-title":"Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Task Force on Postovulatory Methods of Fertility Regulation","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib30","first-page":"271","article-title":"Meclizine for prevention of nausea associated with use of emergency contraceptive pills: a randomized trial","volume":"95","author":"Raymond","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0010-7824(00)00178-5","article-title":"Ectopic gestation following emergency contraceptive pill administration","volume":"62","author":"Nielsen","year":"2000","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib32","first-page":"1443","article-title":"American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists, Number 69, December 2005 (replaces Practice Bulletin Number 25, March 2001). Emergency contraception","volume":"106","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib33","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(98)07190-6","article-title":"Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Task Force on Postovulatory Methods of Fertility Regulation","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib34","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1471-0528.2002.01371.x","article-title":"A randomised study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception","volume":"109","author":"Ashok","year":"2002","journal-title":"BJOG"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib35","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM199210083271501","article-title":"Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception","volume":"327","author":"Glasier","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib36","series-title":"SEER cancer statistics review, 1975\u20132000","author":"Ries","year":"2003"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib37","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(96)90806-5","article-title":"Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer","volume":"347","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib38","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa013202","article-title":"Oral Contraceptives and the risk of breast cancer","volume":"346","author":"Marchbanks","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib39","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.4065\/81.10.1290","article-title":"Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis","volume":"81","author":"Kahlenborn","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib40","first-page":"189","article-title":"Risk of breast cancer associated with short-term use of oral contraceptives","volume":"18","author":"Folger","year":"2007","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib41","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/0140-6736(91)91498-J","article-title":"Breast cancer and depot-medroxyprogesterone acetate: a multi-national study. WHO Collaborative Study of Neoplasia and Steroid Contraceptives","volume":"338","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib42","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1001\/jama.1995.03520340055036","article-title":"Depot medroxyprogesterone acetate and breast cancer. A pooled analysis from the World Health Organization and New Zealand studies","volume":"273","author":"Skegg","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib43","series-title":"Estrogens and progestogens in clinical practice","first-page":"831","article-title":"The influence of steroids on gynecologic cancers","author":"Schlesselman","year":"1999"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib44","first-page":"796","article-title":"Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development","volume":"257","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib45","first-page":"277","article-title":"Use of oral contraceptives and endometrial cancer risk (Sweden)","volume":"10","author":"Weiderpass","year":"1999","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib46","first-page":"186","article-title":"Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives","volume":"49","year":"1991","journal-title":"Int J Cancer"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib47","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0029-7844(95)00022-J","article-title":"Net effect of oral contraceptive use on the risk of cancer in women in the United States","volume":"85","author":"Schlesselman","year":"1995","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib48","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1056\/NEJM198703123161102","article-title":"The reduction in risk of ovarian cancer associated with oral contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib49","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/jnci\/94.1.32","article-title":"Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk","volume":"94","author":"Schildkraut","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib50","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJM199808133390702","article-title":"Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group","volume":"339","author":"Narod","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib51","first-page":"419","article-title":"The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer","volume":"83","author":"Gross","year":"1994","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib52","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/(SICI)1097-0215(19990505)81:3<357::AID-IJC8>3.0.CO;2-1","article-title":"Smoking and oral contraceptives as risk factors for cervical carcinoma in situ","volume":"81","author":"Ylitalo","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib53","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1054\/bjoc.1999.1100","article-title":"Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection","volume":"82","author":"Kjellberg","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib54","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/gye.15.1.23.28","article-title":"The evidence for an etiological relationship between oral contraceptive use and dysplastic change in cervical tissue","volume":"15","author":"Salazar","year":"2001","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib55","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(02)08150-3","article-title":"Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study","volume":"359","author":"Moreno","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib57","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(02)08151-5","article-title":"Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study","volume":"359","author":"Munoz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib58","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1054\/bjoc.2000.1622","article-title":"Oral contraceptives and colorectal cancer risk: a meta-analysis","volume":"84","author":"Fernandez","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib59","first-page":"569","article-title":"Spinal bone density in women using depot medroxyprogesterone contraception","volume":"92","author":"Cundy","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib60","first-page":"736","article-title":"Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health","volume":"95","author":"Petitti","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib61","first-page":"576","article-title":"A prospective, controlled study of the effects of hormonal contraception on bone mineral density","volume":"98","author":"Berenson","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib62","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.contraception.2006.02.004","article-title":"Bone mineral density and depot medroxyprogesterone acetate","volume":"73","author":"Albertazzi","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib63","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/01.AOG.0000117082.49490.d5","article-title":"Effects of hormonal contraception on bone mineral density after 24 months of use","volume":"103","author":"Berenson","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib64","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.fertnstert.2004.04.064","article-title":"bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate","volume":"82","author":"Clark","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib65","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.contraception.2005.12.010","article-title":"Progestogen-only contraception and bone density: a systematic review","volume":"73","author":"Curtis","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib66","first-page":"5","article-title":"American College of Obstetricians and Gynecologists. ACOG committee revises recommendations on OCs with third-generation progestins","volume":"42","year":"1998","journal-title":"ACOG Today"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib67","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/bmj.308.6923.247","article-title":"Recovery of bone density in women who stop using medroxyprogesterone acetate","volume":"308","author":"Cundy","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib68","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1046\/j.1365-2265.1998.00582.x","article-title":"The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal postmenopausal women","volume":"49","author":"Orr-Walker","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib69","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/00001648-200209000-00015","article-title":"Injectable hormone contraception and bone density: results from a prospective study","volume":"13","author":"Scholes","year":"2002","journal-title":"Epidemiology"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib70","first-page":"233","article-title":"Bone mineral density in women using depot medroxyprogesterone acetate for contraception","volume":"93","author":"Scholes","year":"1999","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib71","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0022-3476(96)70148-8","article-title":"A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives","volume":"129","author":"Cromer","year":"1996","journal-title":"J Pediatr"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib72","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpag.2003.11.017","article-title":"Bone mineral density in adolescent females using depot medroxyprogesterone acetate","volume":"17","author":"Lara-Torre","year":"2004","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib73","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jadohealth.2004.07.005","article-title":"Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls","volume":"35","author":"Cromer","year":"2004","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib74","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jadohealth.2004.09.003","article-title":"Contraceptive use in teens: a threat to bone health?","volume":"35","author":"Gold","year":"2004","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib75","series-title":"Depo-Provera Contraceptive Injection medroxyprogesterone acetate injectable suspension, USP","year":"2006"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib76","series-title":"Depo-subQ Provera 104, medroxyprogesterone acetate injectable suspension, 104 mg\/0.65 mL","year":"2005"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib77","first-page":"203","article-title":"American College of Obstetricians and Gynecologists, Women's Health Care Physicians. Osteoporosis: clinical management guidelines for obstetrician-gynecologists. ACOG Practice Bulletin, no. 50, January 2003","volume":"103","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib78","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0010-7824(95)00121-P","article-title":"Differential effects on bone density of progestogen-only methods for contraception in premenopausal women","volume":"52","author":"Naessen","year":"1995","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib79","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-2001-18642","article-title":"Implant contraception","volume":"19","author":"Meckstroth","year":"2001","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib80","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2265.1993.tb02422.x","article-title":"Effects of norethisterone on bone related biochemical variables and forearm bone mineral in post-menopausal osteoporosis","volume":"39","author":"Horowitz","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib81","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1001\/archinte.1991.00400100053009","article-title":"Oral contraceptive use may protect against low bone mass. Henry Ford Hospital Osteoporosis Cooperative Research Group","volume":"151","author":"Kleerekoper","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib82","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(98)09044-8","article-title":"Oral-contraceptive use and risk of hip fracture: a case-control study","volume":"353","author":"Michaelsson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib83","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0015-0282(01)01936-7","article-title":"Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate","volume":"76","author":"Perrotti","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib84","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0010-7824(95)00036-A","article-title":"Bone mass and long-term monophasic oral contraceptive treatment in young women","volume":"51","author":"Polatti","year":"1995","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib85","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0010-7824(00)00086-X","article-title":"Low-dose oral contraceptives and bone mineral density: an evidence-based analysis","volume":"61","author":"Kuohung","year":"2000","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib86","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0015-0282(00)00719-6","article-title":"Oral contraceptive use by teenage women does not affect peak bone mass: a longitudinal study","volume":"74","author":"Lloyd","year":"2000","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib87","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0010-7824(03)00147-1","article-title":"Longitudinal changes in bone density in relation to oral contraceptive use","volume":"68","author":"Reed","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib88","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.contraception.2006.01.006","article-title":"Oral contraceptive use and risk of fractures","volume":"73","author":"Vestergaard","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib89","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/humupd\/5.6.721","article-title":"Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks","volume":"5","author":"Farley","year":"1999","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib90","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa003216","article-title":"Oral contraceptives and the risk of myocardial infarction","volume":"345","author":"Tanis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib91","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S0140-6736(97)02358-1","article-title":"Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib92","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.STR.0000015345.61324.3F","article-title":"Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke","volume":"33","author":"Kemmeren","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib93","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.318.7175.13","article-title":"Migraine and stroke in young women: case-control study. The World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","volume":"318","author":"Chang","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib94","first-page":"1100","article-title":"WHO Programme for Mapping Best Practices in Reproductive Health. Contraception for women in selected circumstances","volume":"99","author":"Curtis","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib95","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1161\/01.STR.29.11.2277","article-title":"Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies","volume":"29","author":"Schwartz","year":"1998","journal-title":"Stroke"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib96","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1212\/01.WNL.0000154528.21485.3A","article-title":"Migraine, headache, and the risk of stroke in women: a prospective study","volume":"64","author":"Kurth","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib97","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1212\/01.WNL.0000158326.31368.04","article-title":"Headache, cerebrovascular symptoms, and stroke: the Atherosclerosis Risk in Communities Study","volume":"64","author":"Stang","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib98","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/bmj.310.6983.830","article-title":"Case control study of migraine and risk of ischemic stroke in young women","volume":"310","author":"Tzourio","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib99","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/bmj.38302.504063.8F","article-title":"Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies","volume":"330","author":"Etminan","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib100","first-page":"1100","article-title":"Contraception for women in selected circumstances","volume":"99","author":"Curtis","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib101","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/oxfordjournals.aje.a115799","article-title":"Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease","volume":"133","author":"Gerstman","year":"1991","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib102","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(95)91927-9","article-title":"Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","volume":"346","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib103","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/bmj.323.7305.131","article-title":"Third generation oral contraceptives and risk of venous thrombosis: meta-analysis","volume":"323","author":"Kemmeren","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib104","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-2001-18638","article-title":"The risks of oral contraceptive pills","volume":"19","author":"Pymar","year":"2001","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib105","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.contraception.2006.02.002","article-title":"Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel","volume":"73","author":"Jick","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib106","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(94)90286-0","article-title":"Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation","volume":"344","author":"Vandenbroucke","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib107","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/13625180008500383","article-title":"Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?","volume":"5","author":"Spannagl","year":"2000","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib108","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJM200105173442007","article-title":"Oral contraceptives and the risk of venous thrombosis","volume":"344","author":"Vandenbroucke","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2008.08.093_bib109","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.ATV.19.3.700","article-title":"Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis","volume":"19","author":"Martinelli","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028208037175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028208037175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T07:27:17Z","timestamp":1758007637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0015028208037175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":109,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0015028208037175"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2008.08.093","relation":{},"ISSN":["0015-0282"],"issn-type":[{"value":"0015-0282","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hormonal contraception: recent advances and controversies","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2008.08.093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}